JP2010539187A5 - - Google Patents

Download PDF

Info

Publication number
JP2010539187A5
JP2010539187A5 JP2010525103A JP2010525103A JP2010539187A5 JP 2010539187 A5 JP2010539187 A5 JP 2010539187A5 JP 2010525103 A JP2010525103 A JP 2010525103A JP 2010525103 A JP2010525103 A JP 2010525103A JP 2010539187 A5 JP2010539187 A5 JP 2010539187A5
Authority
JP
Japan
Prior art keywords
group
dioxo
dihydropyrimidin
tert
butyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010525103A
Other languages
English (en)
Japanese (ja)
Other versions
JP5734655B2 (ja
JP2010539187A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/076592 external-priority patent/WO2009039134A1/en
Publication of JP2010539187A publication Critical patent/JP2010539187A/ja
Publication of JP2010539187A5 publication Critical patent/JP2010539187A5/ja
Application granted granted Critical
Publication of JP5734655B2 publication Critical patent/JP5734655B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010525103A 2007-09-17 2008-09-17 抗感染症ピリミジンおよびその使用 Expired - Fee Related JP5734655B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US97288107P 2007-09-17 2007-09-17
US60/972,881 2007-09-17
US9679208P 2008-09-13 2008-09-13
US61/096,792 2008-09-13
PCT/US2008/076592 WO2009039134A1 (en) 2007-09-17 2008-09-17 Anti-infective pyrimidines and uses thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2012221886A Division JP5931683B2 (ja) 2007-09-17 2012-10-04 抗感染症ピリミジンおよびその使用
JP2015082240A Division JP2015187106A (ja) 2007-09-17 2015-04-14 抗感染症ピリミジンおよびその使用

Publications (3)

Publication Number Publication Date
JP2010539187A JP2010539187A (ja) 2010-12-16
JP2010539187A5 true JP2010539187A5 (enExample) 2013-08-15
JP5734655B2 JP5734655B2 (ja) 2015-06-17

Family

ID=40308557

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2010525103A Expired - Fee Related JP5734655B2 (ja) 2007-09-17 2008-09-17 抗感染症ピリミジンおよびその使用
JP2012221886A Expired - Fee Related JP5931683B2 (ja) 2007-09-17 2012-10-04 抗感染症ピリミジンおよびその使用
JP2015082240A Pending JP2015187106A (ja) 2007-09-17 2015-04-14 抗感染症ピリミジンおよびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2012221886A Expired - Fee Related JP5931683B2 (ja) 2007-09-17 2012-10-04 抗感染症ピリミジンおよびその使用
JP2015082240A Pending JP2015187106A (ja) 2007-09-17 2015-04-14 抗感染症ピリミジンおよびその使用

Country Status (21)

Country Link
US (3) US8188104B2 (enExample)
EP (3) EP2639226B1 (enExample)
JP (3) JP5734655B2 (enExample)
CN (4) CN104628654A (enExample)
AT (1) ATE519746T1 (enExample)
CA (2) CA2849420C (enExample)
CY (3) CY1115514T1 (enExample)
DK (3) DK2368882T3 (enExample)
ES (3) ES2368879T3 (enExample)
HR (2) HRP20110809T1 (enExample)
HU (1) HUS1500013I1 (enExample)
LT (1) LTC2203431I2 (enExample)
LU (1) LU92666I2 (enExample)
MX (1) MX2010002902A (enExample)
NL (1) NL300729I2 (enExample)
NO (1) NO2015011I1 (enExample)
PL (3) PL2639226T3 (enExample)
PT (3) PT2368882E (enExample)
RU (2) RU2539570C2 (enExample)
SI (2) SI2368882T1 (enExample)
WO (1) WO2009039134A1 (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105693626A (zh) 2007-09-17 2016-06-22 艾伯维巴哈马有限公司 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物
CN104628654A (zh) * 2007-09-17 2015-05-20 艾伯维巴哈马有限公司 抗感染嘧啶及其用途
CN102746239B (zh) * 2007-09-17 2016-02-10 艾伯维巴哈马有限公司 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物
WO2010010017A1 (en) * 2008-07-23 2010-01-28 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
EP2334662A1 (en) 2008-09-26 2011-06-22 F. Hoffmann-La Roche AG Pyrine or pyrazine derivatives for treating hcv
WO2010043721A1 (en) 2008-10-17 2010-04-22 Oryzon Genomics, S.A. Oxidase inhibitors and their use
WO2010084160A1 (en) 2009-01-21 2010-07-29 Oryzon Genomics S.A. Phenylcyclopropylamine derivatives and their medical use
RU2552533C2 (ru) * 2009-03-25 2015-06-10 Эббви Инк. Противовирусные соединения и их применения
EP2421831A1 (en) 2009-04-25 2012-02-29 F. Hoffmann-La Roche AG Heterocyclic antiviral compounds
AR077004A1 (es) 2009-06-09 2011-07-27 Hoffmann La Roche Compuestos heterociclicos antivirales
SG176976A1 (en) 2009-06-24 2012-02-28 Hoffmann La Roche Heterocyclic antiviral compound
BR112012005616A2 (pt) 2009-09-21 2016-06-21 Hoffmann La Roche compostos antivirais heterocíclicos
JP5699152B2 (ja) 2009-09-25 2015-04-08 オリゾン・ジェノミックス・ソシエダッド・アノニマＯｒｙｚｏｎ Ｇｅｎｏｍｉｃｓ Ｓ．Ａ． リジン特異的デメチラーゼ−１阻害剤およびその使用
EP2486002B1 (en) 2009-10-09 2019-03-27 Oryzon Genomics, S.A. Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use
BR112012012085A2 (pt) * 2009-11-21 2016-05-17 Hoffmann La Roche compostos antivirais heterocíclicos
BR112012014299A2 (pt) * 2009-12-14 2016-07-05 Hoffmann La Roche composto de antivírus heterocíclicos
KR20120093428A (ko) * 2009-12-14 2012-08-22 메르크 파텐트 게엠베하 스핑고신 키나아제 저해제
US9186337B2 (en) 2010-02-24 2015-11-17 Oryzon Genomics S.A. Lysine demethylase inhibitors for diseases and disorders associated with Hepadnaviridae
WO2011106574A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Inhibitors for antiviral use
US9216952B2 (en) 2010-03-23 2015-12-22 Abbvie Inc. Process for preparing antiviral compound
JP5868948B2 (ja) 2010-04-19 2016-02-24 オリゾン・ジェノミックス・ソシエダッド・アノニマＯｒｙｚｏｎ Ｇｅｎｏｍｉｃｓ Ｓ．Ａ． リジン特異的脱メチル化酵素１阻害薬およびその使用
EP3461556A1 (en) 2010-07-16 2019-04-03 AbbVie Ireland Unlimited Company Phosphine ligands for catalytic reactions
US8975443B2 (en) 2010-07-16 2015-03-10 Abbvie Inc. Phosphine ligands for catalytic reactions
US9255074B2 (en) 2010-07-16 2016-02-09 Abbvie Inc. Process for preparing antiviral compounds
EP3056486B1 (en) * 2010-07-16 2018-07-11 AbbVie Ireland Unlimited Company Process for preparing intermediates for antiviral compounds
WO2012013728A1 (en) 2010-07-29 2012-02-02 Oryzon Genomics S.A. Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use
US9006449B2 (en) 2010-07-29 2015-04-14 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as LSD1 inhibitors
WO2012020725A1 (ja) * 2010-08-10 2012-02-16 塩野義製薬株式会社 Ｎｐｙ ｙ５受容体拮抗作用を有するヘテロ環誘導体
WO2012045883A1 (en) 2010-10-08 2012-04-12 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012072713A2 (en) * 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
EP2712315B1 (en) 2011-02-08 2021-11-24 Oryzon Genomics, S.A. Lysine demethylase inhibitors for myeloproliferative disorders
CN102675092B (zh) * 2011-03-14 2014-11-05 江苏中丹药物研究有限公司 一种制备2-芳基-2,2-二甲基乙酸甲酯的方法
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
AU2012324803B9 (en) 2011-10-20 2017-08-24 Oryzon Genomics, S.A. (hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
SG11201401066PA (en) 2011-10-20 2014-10-30 Oryzon Genomics Sa (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
SE1450130A1 (sv) 2011-10-21 2014-05-07 Abbvie Inc Förfaranden för att behandla hcv innefattande minst två direktverkande antivirala agenser, ribavirin men inte interferon
EP2583680A3 (en) * 2011-10-21 2013-06-12 Abbvie Inc. Mono (PSI-7977) or combination treatment of DAAs for use in treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
EP2887941B1 (en) 2012-08-21 2018-07-11 AbbVie Ireland Unlimited Company Process for preparing antiviral compounds
JP6266635B2 (ja) * 2012-10-18 2018-01-24 アッヴィ・インコーポレイテッド ピリミジンジオン誘導体化合物の製剤
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
WO2015197028A1 (en) * 2014-06-28 2015-12-30 Sunshine Lake Pharma Co., Ltd. Compounds as hepatitis c virus (hcv) inhibitors and uses thereof in medicine
WO2016105547A1 (en) 2014-12-24 2016-06-30 Concert Pharmaceuticals, Inc. Deuterated dasabuvir
CN108777958B (zh) * 2016-03-17 2021-03-12 Fmc有限公司 将s-对映体转换成其消旋形式的方法
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
CN108290844B (zh) * 2016-05-27 2021-04-30 深圳市塔吉瑞生物医药有限公司 一种取代的萘环化合物及药物组合物及其应用
CN110483496B (zh) * 2019-07-17 2021-05-04 杭州市西溪医院 一类具有尿嘧啶-苯并噻唑结构衍生物、其制备方法及抗hcv药物的应用
CN111518036A (zh) * 2020-04-29 2020-08-11 杭州勇诚睿生物科技有限公司 一种达沙布韦关键中间体的制备方法
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors
CN117466847B (zh) * 2022-07-22 2026-01-27 中国医药工业研究总院有限公司 一种利非斯特中间体苯并呋喃-6-羧酸的制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4239888A (en) 1974-11-04 1980-12-16 Pfizer Inc. 1-Phenyluracils
JPS60243017A (ja) * 1984-05-16 1985-12-03 Kyowa Hakko Kogyo Co Ltd 抗けいれん組成物
AU627906B2 (en) 1989-07-14 1992-09-03 Nissan Chemical Industries Ltd. Uracil derivatives and herbicides containing the same as active ingredient
US5084084A (en) 1989-07-14 1992-01-28 Nissan Chemical Industries Ltd. Uracil derivatives and herbicides containing the same as active ingredient
ATE169915T1 (de) 1990-02-15 1998-09-15 Takeda Chemical Industries Ltd Pyrimidindionderivate, deren herstellung und verwendung
NL9001075A (enExample) * 1990-05-04 1991-12-02 Duphar Int Res
EP0489480A1 (en) * 1990-12-05 1992-06-10 Nissan Chemical Industries Ltd. Uracil derivatives and herbicides containing the same as active ingredient
JPH05213755A (ja) 1992-02-07 1993-08-24 Nikko Kyodo Co Ltd 肝臓障害治療薬
DE19528305A1 (de) 1995-08-02 1997-02-06 Bayer Ag Substituierte Phenyluracile
US6380387B1 (en) 1999-12-06 2002-04-30 Hoffmann-La Roche Inc. 4-Pyrimidinyl-n-acyl-l phenylalanines
PL207160B1 (pl) 1999-12-06 2010-11-30 Hoffmann La Roche Pochodne 4-pirymidynylo-N-acylo-L-fenyloalaniny, związki pośrednie, środek farmaceutyczny i ich zastosowanie
IL167954A (en) 2000-02-04 2007-10-31 Sumitomo Chemical Co History of pyrimidine
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
WO2003068162A2 (en) * 2002-02-14 2003-08-21 Pharmasset Ltd. Modified fluorinated nucleoside analogues
EA200500721A1 (ru) * 2002-11-28 2005-12-29 Шеринг Акциенгезельшафт Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств
KR100589964B1 (ko) * 2003-06-13 2006-06-19 주식회사 엘지생명과학 Ｃ형 간염 바이러스의 억제제
BRPI0413234A (pt) * 2003-08-01 2006-10-03 Genelabs Tech Inc derivados de imidazola bicìclica contra flaviviridae
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
JP2008506702A (ja) * 2004-07-14 2008-03-06 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎を治療するための方法
WO2007058392A1 (ja) * 2005-11-21 2007-05-24 Japan Tobacco Inc. ヘテロ環化合物およびその医薬用途
CN102746239B (zh) * 2007-09-17 2016-02-10 艾伯维巴哈马有限公司 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物
CN105693626A (zh) 2007-09-17 2016-06-22 艾伯维巴哈马有限公司 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物
CN104628654A (zh) * 2007-09-17 2015-05-20 艾伯维巴哈马有限公司 抗感染嘧啶及其用途
WO2010010017A1 (en) 2008-07-23 2010-01-28 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds

Similar Documents

Publication Publication Date Title
JP2010539187A5 (enExample)
HRP20110809T1 (hr) Protuupalni pirimidini i njihove uporabe
RU2013104270A (ru) Производные урацила или тимина для лечения гепатита с
JP2010539188A5 (enExample)
JP2010539186A5 (enExample)
JP5726527B2 (ja) Ｃ型肝炎ウイルス（ｈｃｖ）阻害薬として有用なｎ−フェニル−ジオキソ−ヒドロピリミジン
RU2015144653A (ru) Противовирусные соединения и их применения
JP2015526441A5 (enExample)
JP2013505949A5 (enExample)
JP2007516173A5 (enExample)
JP2020516671A5 (enExample)
JP2006516626A5 (enExample)
JP2019516677A5 (enExample)
AU2014280939B2 (en) Uracil or thymine derivative for treating hepatitis C